Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity

Basic fibroblast growth factor (bFGF), which plays an important role in tumour angiogenesis and progression, provides a potential target for cancer therapy. Here we screened a phage display heptapeptide library with bFGF and identified 11 specific bFGF‐binding phage clones. Two of these clones had identical sequence and the corresponding peptide (referred to as P7) showed high homology to the immunoglobulin‐like (Ig‐like) domain III (D3) of high‐affinity bFGF receptors, FGFR1 (IIIc) and FGFR2 (IIIc). The P7 peptide and its corresponding motif in D3 of FGFRs both carried negative charges and shared similar hydrophobic profiles. Functional analysis demonstrated that synthetic P7 peptides mediate strong inhibition of bFGF‐induced cell proliferation and neovascularization. Our results demonstrate that the P7 peptide is a potent bFGF antagonist with strong antiangiogenetic activity, and might have therapeutic potential in cancer therapy.

[1]  W. Schulz,et al.  Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. , 2003, European urology.

[2]  E. Katchalski‐Katzir,et al.  Isolation of peptides that inhibit binding of basic fibroblast growth factor to its receptor from a random phage-epitope library. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Guoquan Liu,et al.  Quartz crystal microbalance biosensor for recombinant human interferon-beta detection based on antisense peptide approach. , 2007, Analytica chimica acta.

[4]  M. Rusnati,et al.  Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. , 2007, Current pharmaceutical design.

[5]  D. Ambrosetti,et al.  Mechanisms underlying differential responses to FGF signaling. , 2005, Cytokine & growth factor reviews.

[6]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[7]  J. Yamate,et al.  Expressions of vascular endothelial growth factor and basic fibroblast growth factor in tumors induced by two different cloned cell lines established from transplantable rat malignant fibrous histiocytoma. , 2000, The Journal of veterinary medical science.

[8]  G. Fassina,et al.  Inhibition of interleukin-2/p55 receptor subunit interaction by complementary peptides. , 1995, Archives of biochemistry and biophysics.

[9]  M. Eisenstein,et al.  Molecular modeling based mutagenesis defines ligand binding and specificity determining regions of fibroblast growth factor receptors. , 1995, Biochemistry.

[10]  R. Sasada,et al.  Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. , 1991, Cancer research.

[11]  X. Bian,et al.  Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas. , 2000, Analytical and quantitative cytology and histology.

[12]  C. Schmuck,et al.  Peptide Binding by One‐Armed Receptors in Water: Screening of a Combinatorial Library for the Binding of Val‐Val‐Ile‐Ala , 2003, Chembiochem : a European journal of chemical biology.

[13]  A. Yayon,et al.  Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. , 1993, Journal of the National Cancer Institute.

[14]  Joseph Schlessinger,et al.  Crystal Structures of Two FGF-FGFR Complexes Reveal the Determinants of Ligand-Receptor Specificity , 2000, Cell.

[15]  Xiaokun Li,et al.  Inhibition of angiogenesis by a novel small peptide consisting of the active fragments of platelet factor-4 and vasostatin. , 2007, Cancer letters.

[16]  M. Mohammadi,et al.  Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Kan,et al.  Ligand-specific Structural Domains in the Fibroblast Growth Factor Receptor (*) , 1995, The Journal of Biological Chemistry.

[18]  J. Kelly,et al.  HYDROPHOBIC CLUSTER FORMATION IS NECESSARY FOR DIBENZOFURAN-BASED AMINO ACIDS TO FUNCTION AS BETA -SHEET NUCLEATORS , 1994 .

[19]  G. Fassina,et al.  Design of hydropathically complementary peptides for Big Endothelin affinity purification. , 2009, International journal of peptide and protein research.

[20]  Shaun K Olsen,et al.  Receptor Specificity of the Fibroblast Growth Factor Family , 2006, Journal of Biological Chemistry.

[21]  P. Khosravi Shahi,et al.  Tumoral angiogenesis: review of the literature. , 2008, Cancer investigation.

[22]  A. Hamilton,et al.  Peptide and protein recognition by designed molecules. , 2000, Chemical reviews.